Despite the lack of a significant correlation between RAD54L expression and overall survival, higher MYBL2 and RAD54L expression tended to predict a worse prognosis in patients with ovarian cancer (Supplementary Fig. 11c, d). Here, RAD54L is linked to ovarian cancer.